Federal Register / Vol. 89, No. 33 / Friday, February 16, 2024 / Notices 12357 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–N–0008] 

Request for Nominations for Voting 

Members for the Genetic Metabolic 

Diseases Advisory Committee; 

Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

amendment to the notice of the request 

for nominations for voting members 

excluding consumer and industry 

representatives, to serve on the Genetic 

Metabolic Diseases Advisory Committee 

(the Committee) in the Center for Drug 

Evaluation and Research. This request 

for nominations was announced in the 

Federal Register of December 13, 2023. 

The amendment is being made to reflect 

a change in the DATES portion of the 

document. There are no other changes. 

FOR FURTHER INFORMATION CONTACT: 

Moon Choi, Center for Drug Evaluation 

and Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 31, Rm. 2417, Silver Spring, 

MD 20993–0002, 301–796–2894, email: 

GEMDAC@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of December 13, 2023 

(88 FR 86337), FDA announced a 

request for nominations for voting 

members excluding consumer and 

industry representatives, to serve on the 

Genetic Metabolic Diseases Advisory 

Committee. On page 86337, in the 

second column, the DATES portion of the 

document is changed to read as follows: 

Nominations received on or before 

March 12, 2024, will be given first 

consideration for membership on the 

Committee. Nominations received after 

March 12, 2024, will be considered for 

nomination to the Committee as later 

vacancies occur. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: February 12, 2024. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2024–03302 Filed 2–15–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Training in 

Primary Care Medicine and Dentistry 

Meeting Cancellation 

AGENCY: Health Resources and Services 

Administration; Department of Health 

and Human Services. 

ACTION: Notice of meeting cancellation. 

SUMMARY: This is to notify the public 

that the March 25–26, 2024, meeting of 

the Advisory Committee on Training in 

Primary Care Medicine and Dentistry is 

cancelled. 

FOR FURTHER INFORMATION CONTACT: 

Shane Rogers, Designated Federal 

Officer, Advisory Committee on 

Training in Primary Care Medicine and 

Dentistry, 5600 Fishers Lane, Room 

15N142, Rockville, Maryland 20857, 

telephone: (301) 443–5260 or email: 

srogers@hrsa.gov. 

SUPPLEMENTARY INFORMATION: This 

meeting was announced in the Federal 

Register on Friday, December 15, 2023 

(88 FR 86909). Future meetings will be 

held on August 2, 2024, and another 

date this calendar year that will be 

announced at least 30 days before the 

meeting date through the Federal 

Register. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–03261 Filed 2–15–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting Amended Notice of Meeting 

Notice is hereby given of a change in 

the virtual meeting of the Biomedical 

Library, Informatics and Data Science 

Review Committee, May 17–18, 2024, 

which was published in the Federal 

Register on December 21, 2023, 2023, 88 

FR 88407. 

The meeting will be amended to 

change the meeting dates from March 7– 

8, 2024, to March 7, 2024. The meeting 

will be closed to the public. 

Dated: February 12, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03212 Filed 2–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Integration of Novel 

Measures for Improved Classification of Type 

2 Diabetes Consortium Review. 

Date: March 19, 2024. 

Time: 10:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, NIDDK 

Democracy II, Suite 7000A, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: February 12, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03211 Filed 2–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 


lotter on DSK11XQN23PROD with NOTICES1
12358 Federal Register / Vol. 89, No. 33 / Friday, February 16, 2024 / Notices 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK RC2 Review. 

Date: March 21, 2024. 

Time: 11:30 a.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, NIDDK 

Democracy II, Suite 7000A, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7351, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: February 12, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03208 Filed 2–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. The meetings will 

be closed to the public in accordance 

with the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Quantification of Drugs of Abuse and Related 

Substances Compounds in Biological 

Specimens. 

Date: March 1, 2024. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 827–4471, 

ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Mechanism for Time-Sensitive Drug Abuse 

Research. 

Date: March 12, 2024. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Contact Person: Sudhirkumar U. 

Yanpallewar, M.D., Scientific Review Officer, 

Scientific Review Branch, National Institute 

on Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 443–4577, sudhirkumar.yanpallewar@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: February 13, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03327 Filed 2–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

[Docket No. USCBP–2024–0001] 

Commercial Customs Operations 

Advisory Committee 

AGENCY: U.S. Customs and Border 

Protection (CBP), Department of 

Homeland Security (DHS). 

ACTION: Committee management; notice 

of open Federal advisory committee 

meeting. 

SUMMARY: The Commercial Customs 

Operations Advisory Committee (COAC) 

will hold its quarterly meeting on 

Wednesday, March 6, 2024, in 

Charleston, SC. The meeting will be 

open for the public to attend in person 

or via webinar. The in-person capacity 

is limited to 75 persons for public 

attendees. 

DATES: The COAC will meet on 

Wednesday, March 6, 2024, from 1 p.m. 

to 5 p.m. eastern standard time (EST). 

Please note that the meeting may close 

early if the committee has completed its 

business. Registration to attend inperson and comments must be 

submitted no later than March 1, 2024. 

ADDRESSES: The meeting will be held at 

the Doubletree Hilton, 7401 Northwood 

Boulevard, Charleston, SC 29406 in the 

Lower/Upper Altitude Ballroom. For 

virtual participants, the webinar link 

and conference number will be posted 

by 5 p.m. EST on March 5, 2024, at 

https://www.cbp.gov/trade/stakeholderengagement/coac. For information or to 

request special assistance for the 

meeting, contact Mrs. Latoria Martin, 

Office of Trade Relations, U.S. Customs 

and Border Protection, at (202) 344– 

1440, as soon as possible. 

Comments may be submitted by one 

of the following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Search for Docket 

Number USCBP–2024–0001. To submit 

a comment, click the ‘‘Comment’’ button 

located on the top-left hand side of the 

docket page. 

• Email: tradeevents@cbp.dhs.gov. 

Include Docket Number USCBP–2024– 

0001 in the subject line of the message. 

Comments must be submitted in 

writing no later than March 1, 2024, and 

must be identified by Docket No. 

USCBP–2024–0001. All submissions 

received must also include the words 

‘‘Department of Homeland Security.’’ 

All comments received will be posted 

without change to https://www.cbp.gov/ 

trade/stakeholder-engagement/coac/ 

coac-public-meetings and 

www.regulations.gov. Therefore, please 

refrain from including any personal 

information you do not wish to be 

posted. You may wish to view the 

Privacy and Security Notice, which is 

available via a link on 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Latoria Martin, Office of Trade 

Relations, U.S. Customs and Border 

Protection, 1300 Pennsylvania Avenue 

NW, Room 3.5A, Washington, DC 

20229, (202) 344–1440; or Ms. Felicia 

M. Pullam, Designated Federal Officer, 

at (202) 344–1440 or via email at 

tradeevents@cbp.dhs.gov. 


lotter on DSK11XQN23PROD with NOTICES1